Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Historically, full-empty AAV capsid separation performed using an ultracentrifugation density gradient has been the gold standard for downstream operations in the gene therapy space. However, this approach requires high levels of manual labour, which only intensifies at larger production scales.
To solve this challenge the industry has been working to move towards the anion exchange chromatography (AEX) method, which is seen as a promising and innovative alternative. This technique can both reduce process time and potentially improve yields – but is not without its own drawbacks and limitations.
This webinar will compare these two approaches to empty-full separation, and consider the key benefits and challenges when using each. Additionally, a case study on the potential impact of switching from ultracentrifugation to AEX for the separation of full-empty capsids for the serotype AAV9 will be explored.
Attend this webinar for insights into:
-
The critical importance of successful full-empty AAV capsid separation to ensure purity of the final product
-
Key benefits and limitations of ultracentrifugation versus AEX for full-empty capsid separation
-
Case study data comparing ultracentrifugation with AEX chromatography when producing AAV9
